Patent US5562913A successfully refreshed from Google Patents.
US5562913A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Formulation for use in smokers
Assignee: Scotia Holdings PLC
•
Filing: 1994-03-18
•
Granted: 1996-10-08
•
Expires: 2014-03-18
Abstract
Abstract Preparation of a formulation for mitigating ill effects of smoking, wherein one or more of the n-6 EFAs selected from GLA, DGLA and AA, and one or more of the n-3 EFAs selected from SA, 20:4n-3, EPA, DPA or DHA are used, preferably so that the daily dose of each fatty acid is within the range 1 mg to 100g/day. The formulation may in many other purposes be used in the treatment or prevention of ageing of the skin of smokers.
Inventors
- 👤 David F. Horrobin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 04:45
CPC Classifications
A; A23; A23L; A23L33/00; A23L33/10; A23L33/115; A23L33/12; A61; A61Q; A61Q19/00; A61Q19/08; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/20; A61K31/202; A61K8/00; A61K8/18; A61K8/30; A61K8/33; A61K8/36; A61K8/361; A61K8/67; A61K9/00; A61K9/06; A23V; A23V2002/00; A23V2200/00; A23V2200/30; A23V2200/318; A23V2250/00; A23V2250/18; A23V2250/186; Y; Y10; Y10S; Y10S424/00; Y10S424/05
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
110 words
A method of treating n-6 or n-3 essential fatty acid deficits in smokers wherein there is administered to a smoker a formulation comprising: (a) at least one of the n-6 essential fatty acids selected from the group consisting of gamma-linolenic acid (GLA), dihomo-gamma-linolenic acid (DGLA) and arachidonic acid (AA); or (b) at least one n-3 essential fatty acid selected from the group consisting of stearidonic acid (SA), 8,11,14-17-eicosatetraenoic acid (20:4n-3), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA); or (c) a mixture of (a) and (b); so that the daily dose of each fatty acid administered is within the range of 1 mg to 100 g per day.
Claim 2
Independent Claim
110 words
A method of treating n-6 or n-3 essential fatty acid deficits in smokers wherein there is administered to a smoker a formulation comprising: (a) at least one of the n-6 essential fatty acids selected from the group consisting of gamma-linolenic acid (GLA), dihomo-gamma-linolenic acid (DGLA) and arachidonic acid (AA); or (b) at least one n-3 essential fatty acid selected from the group consisting of stearidonic acid (SA), 8,11,14-17-eicosatetraenoic acid (20:4n-3), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA); or (c) a mixture of (a) and (b); so that the daily dose of each fatty acid administered is within the range of 1 mg to 100 g per day.
Claim 3
Independent Claim
71 words
A method of mitigating the ill effects of smoking, wherein there is administered to a smoker, a formulation of one or more the n-6 EFAs selected from the group consisting of GLA, DGLA and AA, and/or one or more of the n-3 EFAs selected from SA, 20:4n-3, EPA, DPA and DHA, so that the daily dose of each fatty acid is within the range 1 mg to 100 g per day.
Claim 4
Independent Claim
71 words
A method of mitigating the ill effects of smoking, wherein there is administered to a smoker, a formulation of one or more the n-6 EFAs selected from the group consisting of GLA, DGLA and AA, and/or one or more of the n-3 EFAs selected from SA, 20:4n-3, EPA, DPA and DHA, so that the daily dose of each fatty acid is within the range 1 mg to 100 g per day.
Claim 5
Dependent Claim
23 words
The method according to claim 1 or claim 2 wherein the formulation comprises both n-6 essential fatty acids and n-3 essential fatty acids.
Claim 6
Dependent Claim
45 words
The method according to claim 1 or claim 2 wherein the formulation is a nutritional supplement in oil, powder, whip, foam, granule, flake or mousse form and wherein the fatty acids are present in a concentration of from 0.001 to 50% by weight in total.
Claim 7
Dependent Claim
49 words
The method according to claim 1 or claim 2 wherein the formulation is a topical preparation for absorption through the skin, in ointment, lotion, cream, oil, stick or patch form and wherein the fatty acids are present in a concentration of from 0.001 to 50% by weight in total.
Claim 8
Independent Claim
106 words
A method of treating untimely ageing of the skin in smokers, wherein there is administered to a smoker, a formulation comprising: (a) at least one of the n-6 essential fatty acids selected from the group consisting of gamma-linolenic acid (GLA), dihomo-gamma-linolenic acid (DGLA) and arachidonic acid (AA); or (b) at least one n-3 essential fatty acid selected from the group consisting of stearidonic acid (SA), 8,11,14-17-eicosatetraenoic acid (20:4n-3), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA); or (c) a mixture of (a) and (b); so that the daily dose of each fatty acid is within the range 1 mg to 100 g per day.
Claim 9
Independent Claim
106 words
A method of treating untimely ageing of the skin in smokers, wherein there is administered to a smoker, a formulation comprising: (a) at least one of the n-6 essential fatty acids selected from the group consisting of gamma-linolenic acid (GLA), dihomo-gamma-linolenic acid (DGLA) and arachidonic acid (AA); or (b) at least one n-3 essential fatty acid selected from the group consisting of stearidonic acid (SA), 8,11,14-17-eicosatetraenoic acid (20:4n-3), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA); or (c) a mixture of (a) and (b); so that the daily dose of each fatty acid is within the range 1 mg to 100 g per day.
Claim 10
Dependent Claim
20 words
The method according to claim 6 wherein the formulation comprises both n-6 essential fatty acids and n-3 essential fatty acids.
Claim 11
Dependent Claim
42 words
The method according to claim 6 wherein the formulation is a nutritional supplement in oil, powder, whip, foam, granule, flake or mousse form and wherein the fatty acids are present in a concentration of from 0.001 to 50% by weight in total.
Claim 12
Dependent Claim
46 words
The method according to claim 6 wherein the formulation is a topical preparation for absorption through the skin, in ointment, cream lotion, oil, stick or patch form and wherein the fatty acids are present in a concentration of from 0.001 to 50% by weight in total.
References Cited (Backward Citations)
GB1446431A
Cited
FR2197605A1
Cited
BE901390A
Cited
GB2151924A
Cited
FR2597337A2
Cited
JPS62138411A
Cited
FR2609630A1
Cited
JPS63277604A
Cited
EP0334507A2
Cited
JPH0253706A
Cited
WO1990011073A1
Cited
AU5911590A
Cited
AU6213590A
Cited
WO1991017670A1
Cited
US5158975A
Cited
WO1993006812A2
Cited
AU4474893A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-10-08 | 2000-04-08 | 2000-10-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-10-08 | 2004-04-08 | 2004-10-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-10-08 | 2008-04-08 | 2008-10-08 | $7700.00 | Window Closed / Lapsed |